Results 141 to 150 of about 103,961 (275)

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

Acta Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen, Hoi‐Chun Chan, Chi‐Ming Chan   +2 more
wiley   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, EarlyView.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors

British Journal of Haematology, EarlyView.
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani, Vittorio Stefoni, Beatrice Casadei, Carla Pelusi, Valentina Lo Preiato, Uberto Pagotto, Anna Buganè, Cinzia Pellegrini, Alessandro Broccoli, Pier Luigi Zinzani   +9 more
wiley   +1 more source

Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]

Front Oncol
Madar IH, Kammarambath SR.
europepmc   +1 more source

Clinical Impact of Nivolumab in Sinonasal Mucosal Melanoma: A 14-Year Single-Center Retrospective Study and Comprehensive Literature Review. [PDF]

Cancers (Basel)
Terazawa K, Utakata R, Iinuma R, Kuroki M, Yamada T, Ishihara H, Kawaura R, Okuda H, Mori K, Shibata H, Obara N, Umeda M, Ikeda R, Saijo K, Ogawa T.   +14 more
europepmc   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source

Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report. [PDF]

Cancer Rep (Hoboken)
Patel R, Post-Zwicker L, Kaur V.
europepmc   +1 more source

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta‐analysis

BJU International, EarlyView.
Objective To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle‐invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder‐sparing strategies.
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Alessandro Dematteis, Keiichiro Miyajima, Shota Inoue, Katharina Oberneder, Markus von Deimling, Victor M. Schuettfort, Malte W. Vetterlein, Bernadett Szabados, Pawel Rajwa, Pierre I. Karakiewicz, Jeremy Yuen‐Chun Teoh, Margit Fisch, Shahrokh F. Shariat   +15 more
wiley   +1 more source

Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report. [PDF]

Am J Case Rep
Vromans AM, Constantinou M.
europepmc   +1 more source